Roche receives CE Mark for VENTANA FOLR1

Roche receives CE Mark for VENTANA FOLR1 (FOLR1-2.1) RxDx ...

Roche receives CE Mark for VENTANA FOLR1 (FOLR1-2.1) RxDx Assay as the first IHC-based companion diagnostic to identify ovarian cancer patients ...

Roche's VENTANA FOLR1 (FOLR1-2.1) RxDx Assay Gets CE Mark ...

(RTTNews) - Swiss drug major Roche Group (RHHBY) announced Monday that it has received CE Mark for its VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, ...

VENTANA® FOLR1 (FOLR1-2.1) RxDx Assay - Roche Diagnostics

Roche announced today the approval of the CE Mark for the VENTANA HER2 (4B5) ... Roche's VENTANA PD-L1 (SP263) Assay receives CE IVD approval to ...

Roche receives CE Mark for Ventana FOLR1 RxDx Assay - TipRanks

Roche (RHHBY) announced that it has received CE Mark for its Ventana FOLR1 RxDx Assay. This is the first immunohistochemistry, or IHC, ...

Roche-receives-CE-Mark-for-VENTANA-FOLR1 ... - Larvol Delta

https://www.prnewswire.com/news-releases/roche-receives-ce-mark-for-ventana-folr1-folr1-2-1-rxdx-assay-as-the-first-ihc-based-companion ...

VENTANA® PD-L1 (SP263) Assay, CE-IVD - Roche Diagnostics

Allowing optimal lung tissue management through PD-L1 testing of archived unstained slides within 12 months. * IC staining with this assay is not used to assess ...

Ventana Precision Oncology News

The FDA also approved Roche's Ventana FOLR1 (FOLR1-2.1) RxDx Assay as a ... Roche Gets Expanded CE Mark for Ventana PD-L1 Assay to ID NSCLC Patients for Tecentriq.

Roche obtains CE Mark for first companion diagnostic to identify ...

Roche announced today the approval of the CE Mark for the VENTANA HER2 (4B5) test to identify metastatic breast cancer patients with low ...

Health Stocks News on X: "Roche receives CE Mark for VENTANA ...

Roche receives CE Mark for VENTANA FOLR1 (FOLR1-2.1) RxDx Assay as the first IHC-based companion diagnostic to identify ovarian cancer ...

VENTANA® PD-L1 (SP142) Assay, CE-IVD - Roche Diagnostics

VENTANA PD-L1 (SP142) Assay is the first and only CE-IVD marked test for TECENTRIQ in triple–negative breast cancer (TNBC), urothelial carcinoma (UC) and non- ...

Novel diagnostic assay for gastric and gastroesophageal junction ...

Novel diagnostic assay for gastric and gastroesophageal junction cancer receives CE Mark approval. Roche. Roche obtains CE certification for VENTANA CLDN18 ...

Roche receives FDA approval for VENTANA FOLR1 (FOLR1-2.1 ...

Roche receives FDA approval for VENTANA FOLR1 (FOLR1-2.1) RxDx Assay as the first IHC-based companion diagnostic to identify ovarian cancer ...

Untitled

Roche's VENTANA PD-L1 (SP263) Assay receives CE IVD approval ...

The VENTANA PD-L1 (SP263) Assay is available in countries accepting the CE mark as a companion diagnostic to identify non-small cell lung cancer (NSCLC) ...

Roche receives FDA approval for VENTANA FOLR1 ... - PR Newswire

The first immunohistochemistry (IHC) companion diagnostic test to aid in identifying epithelial ovarian cancer (EOC) patients who are eligible for targeted ...

AbbVie Receives European Commission Approval of ELAHERE ...

... receives CE Mark. NORTH CHICAGO, Ill., Nov. 18, 2024 ... To determine biomarker status, patients can be tested with Roche's VENTANA® FOLR1 ...

Roche: CE marking in ovarian cancer - MarketScreener

Roche announced on Monday that it has received CE marking for Ventana ... FOLR1-positive ovarian cancers resistant to conventional ...

VENTANA® Kappa and Lambda Dual ISH mRNA Probe Cocktail

Roche announced today the approval of the CE Mark for the VENTANA HER2 ... Roche receives FDA approval for VENTANA FOLR1 (FOLR1-2.1) RxDx Assay as the ...

In the News - Oklahoma Society of Clinical Oncology

Roche receives CE Mark for VENTANA FOLR1 (FOLR1-2.1) RxDx Assay as the first IHC-based companion diagnostic to identify ovarian cancer patients eligible for ...